Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Construction method for physiological abundance range of N-glycopeptide of healthy people and application of construction method

A glycopeptide and physiological technology, which is applied to the construction of the physiological abundance range of N-glycopeptide in healthy people and its application field, can solve the problems of difficulty in judging the difference of N-glycopeptide and limiting the screening of tumor candidate markers.

Active Publication Date: 2021-06-25
BEIJING PROTEOME RES CENT +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, it is difficult to judge whether the differences in N-glycopeptides found in clinical disease biomarker research come from normal physiological fluctuations, inter-individual differences, or changes caused by diseases. Candidate marker screening studies in real samples

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Construction method for physiological abundance range of N-glycopeptide of healthy people and application of construction method
  • Construction method for physiological abundance range of N-glycopeptide of healthy people and application of construction method
  • Construction method for physiological abundance range of N-glycopeptide of healthy people and application of construction method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Example 1 Constructing the physiological abundance range of N-glycopeptides in healthy people

[0066] 1. Large-scale (in advance, the N-glycoproteome identification accumulation curve of 40 healthy people was investigated, in which the accumulation identification quantity of N-glycoprotein and N-glycosylation site was reached when the number of samples reached 14 cases and tends to be saturated after 20 cases) to determine the N-glycopeptide quantitative value in the physiological samples of healthy people.

[0067] Determination of the quantitative value of N-glycopeptide in physiological samples of 291 healthy volunteers, extraction of urine protein after acetone precipitation, reduction of alkylation and enzymatic digestion of peptide segment, and N-glycopeptide analysis by hydrophilic interaction chromatography (HILIC) method - Glycopeptides were enriched, N-glycan chains were cut off with peptide N-glycoamidase (PNGase F), desalted and heat-dried for mass spectrom...

Embodiment 2

[0084] Example 2 Screening for Abnormal N-Glycopeptide Potential Markers in Patients with Lung Cancer

[0085] S1. Determination of the quantitative value of N-glycopeptide in physiological samples (morning urine) of 50 lung cancer patients before treatment. The determination method refers to step 1 in Example 1.

[0086] A total of 3133 N-glycopeptides were identified from the pre-treatment samples of 50 lung cancer patients and the 291 healthy human samples in Example 1. Such as figure 1 As shown, through principal component analysis, lung cancer samples can be clearly distinguished from healthy samples.

[0087] S2. Compare the quantitative value of each N-glycopeptide identified in the physiological sample of each patient with the physiological abundance range of the N-glycopeptide in the healthy population constructed in Example 1, and the N-glycopeptide whose quantitative value falls outside the range Obtaining all abnormal N-glycopeptides in the patient's physiologica...

Embodiment 3

[0104] Example 3 Screening and analysis of abnormal N-glycopeptides in 20% of lung cancer patient samples

[0105] Molecular typing research using pre-treatment samples (morning urine) of 50 patients with lung cancer: the specific steps are as follows:

[0106] Using 740 N-glycopeptides abnormally expressed in more than 20% of the total number of samples, the differences among samples of lung cancer patients were investigated to carry out molecular typing.

[0107] see results Figure 4 : Using a consensus clustering algorithm, these samples can be divided into four subtypes.

[0108] Figure 5 Among them, a total of 91 key N-glycopeptides were screened out from 740 N-glycopeptides, which can clearly distinguish type 1 from type 3 (C1 and C3). The column directions from left to right are respectively C1, C2, C3 and C4. The row directions from top to bottom are G6, G2, G1, G4, G3 and G5 respectively. The G1 group is mainly related to plasma lipoprotein and IGF function. I...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides a construction method for a physiological abundance range of N-glycopeptide of healthy people, and provides a method for screening potential markers of abnormal N-glycopeptide of diseases on the basis of the constructed physiological abundance range of N-glycopeptide of healthy people. The invention and the construction of the physiological abundance range of the urine N-glycopeptide provide a new method and thought for function and mechanism research and clinical biomarker screening based on urine glycoproteomics.

Description

technical field [0001] The invention specifically relates to a method for constructing a physiological abundance range of N-glycopeptides in healthy people and its application. Background technique [0002] N-glycosylation modification is a ubiquitous protein post-translational modification, which is closely related to a variety of cellular processes, such as molecular recognition and signal transduction, cell adhesion, immune response and apoptosis. Abnormal N-glycosylation modification usually leads to neurodegenerative diseases, diabetes, kidney disease, tumor and inflammatory diseases, etc. Therefore, in-depth investigation of the expression level of N-glycopeptide has significant clinical reference significance for disease prevention, diagnosis, staging, and curative effect tracking evaluation. [0003] Urine is a common biological sample for discovering disease biomarkers, monitoring physical health status, and clinical diagnosis. Changes in the urine proteome derive...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02G01N30/06G01N30/72
CPCG01N30/02G01N30/06G01N30/72
Inventor 秦伟捷董航言李圆圆尚诗婷
Owner BEIJING PROTEOME RES CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com